Journal of Pharmaceutics & Drug Delivery ResearchISSN: 2325-9604

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Colon targeted delivery of the hydroxylase inhibitor dimethyloxallogylcine (DMOG) provides enhanced protection in a murine model of colitis


Murtaza M Tambuwala, Mario C Manresa, Eoin P Cummins, Ivan Coulter and Cormac T Taylor

1 University of Ulster, Northern Ireland

: J Pharm Drug Deliv Res

Abstract


Pharmacologic hydroxylase inhibition represents a potentially important new therapeutic approach to colitis. However, because of potential side effects associated with systemic delivery of hydroxylase inhibitors including unwanted regulation of angiogenic, metabolic and erythropoeitic processes, it is desirable to develop new methods of delivery of such compounds to specific regions of the intestine in order to provide local therapeutic effects without systemic exposure. We have utilized an emulsion-based drug delivery system to attempt to achieve this goal. Initially, we demonstrated that the formulation of the hydroxylase inhibitor DMOG into a novel emulsion-based colon-specific delivery system was without effect upon the biological activity of the drug. The physical process of formulation of DMOG into the colon-specific drug delivery sphere system does not impact upon its biological activity. We next investigated whether formulated DMOG is delivered specifically to the colon when the beads are administered orally to mice. This was investigated by using transgenic mice which ubiquitously express the firefly luciferase gene under the control of a concatomer of NF-kappaB response elements (NRE) to assess NF-kappaB activity in vivo. Our results demonstrate that colon-targeted DMOG delivery resulted in an effective and selective elevation in basal NF-kappaB activity in the colon. We next investigated whether the therapeutic efficacy of colon-specific DMOG delivery in a murine model of DSS-induced colitis. Results from these experiments suggest those colon targeted DMOG beads are protective against experimental colitis in mice at a 40 fold lower dose as compared to systemic administration of DMOG. Our previous work has demonstrated that a significant proportion of the protective effects of DMOG observed in models of intestinal inflammation is a result of enhanced intestinal epithelial barrier function which diminishes the exposure of the mucosal immune system to luminal antigenic material. m

Biography


m.tambuwala@ulster.ac.uk

Track Your Manuscript

Awards Nomination

GET THE APP